Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to support the diagnosis of chronic low back pain. Investors and analysts can review Aclarion’s official regulatory disclosures, including current reports, registration statements, and other filings submitted through the EDGAR system.
For ACON, SEC filings are a primary source of information on financing activities, capital structure, and strategic priorities. For example, a Form 8-K dated October 13, 2025 describes a Securities Purchase Agreement for a registered direct offering of common stock and pre-funded warrants, including expected gross proceeds, pricing terms, and intended use of proceeds. The filing also outlines the role of the placement agent and references the effective Form S-3 registration statement used for the offering.
Through this filings page, users can locate Aclarion’s periodic and transactional filings that detail how the company funds market development, clinical evidence generation, the CLARITY trial, product development and quality, and general corporate purposes. These documents help explain how Aclarion supports commercialization of its Nociscan SaaS platform and its broader strategy in the chronic low back pain market.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, financial implications, and risk factors in plain language. Real-time updates from EDGAR ensure that new 8-Ks, registration statements, and related documents appear promptly. Users can also review filings that relate to equity offerings and other capital markets activities, gaining a clearer view of Aclarion’s liquidity, financing approach, and commitments. This combination of raw filings and AI explanations allows readers to understand complex legal and financial disclosures without parsing every technical detail themselves.
Aclarion, Inc. launched a primary offering of 64,000 shares of common stock and pre-funded warrants for up to 236,000 shares under a Rule 424(b)(5) prospectus supplement. The shares are priced at $8.36 and the pre-funded warrants at $8.35999 each, with a nominal exercise price of $0.00001. The pre-funded warrants do not expire and are exercisable immediately, subject to a 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership cap.
Gross proceeds are $2,507,997.64. After a 7.0% placement fee payable to Dawson James Securities ($175,559.83), proceeds to the company before expenses are $2,332,437.81, with net proceeds estimated at approximately $2.2 million. The company plans to use the funds for market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support.
Common stock trades on Nasdaq as ACON; the pre-funded warrants will not be listed. Shares outstanding were 582,371 as of June 30, 2025, and would be 882,371 assuming full cash exercise of the pre-funded warrants. Dawson James acted on a reasonable best efforts basis, with delivery expected on or about October 14, 2025.